uncoded
DNA & BEYOND

HPV-STI Genomap

Mapping all genotypes in one test

Comprehensive NGS Panel for HPV & STI Genotyping

According to the World Health Organization, HPV causes over 95% of cervical cancer cases, and over 1 million STIs occur globally each day. In India, cervical cancer is the second most common cancer in women, with ~123,907 new cases and ~77,348 deaths each year as per WHO 2023 report. HPV is a common reproductive tract infection, and STIs from viruses, bacteria, and parasites remain a major global health concern. Co-infection with HPV and other STIs raises the risk of poor reproductive health and speeds up cervical cancer. About 5% of women have HPV-16/18, which causes over 83% of invasive cervical cancers.

Traditional molecular tests using multiple PCR assays have limited multiplexing, generate less data, need more hands-on time, and delay results, slowing clinical decisions and affecting patient care. In addition, qPCR lacks strain-level resolution, struggles to detect co-infections, and may yield false results due to contamination. Next-Generation Sequencing (NGS) overcomes these issues with high-throughput, precise detection, and genotyping in a single run, enabling faster and more informed clinical decision-making.

To harness these advantages and address the existing challenges, we are proud to introduce the **HPV-STI Genomap: Mapping all genotypes in one test by UNCODED.**



- Amplicon-based NGS assay for high-throughput, multiplex detection and genotype-level resolution of 41 pathogens (28 HPV genotypes + 13 STI pathogens) in a single-tube test.
- Seamless library preparation workflow that integrates effortlessly with Illumina sequencing platforms.
- Streamlines pathogen profiling from enrichment to interpretation in analysis in a single assay, enabling accurate surveillance, epidemiological insights, and translational research.

Key Features

Enrichment Method

Utilizes Multiplex PCR for efficient and accurate target enrichment, ensuring reliable amplification of the desired genomic regions.

DNA Input Required

Requires a minimum of 20 ng of high-quality, purified DNA, making it suitable for samples with limited input material.

Platform Compatibility

Fully compatible with all Illumina sequencing platforms, including iSeq 100, MiniSeq, MiSeq, MiSeq i100 Series, and NextSeq.

Benchwork Time

Offers a streamlined workflow with approximately 6 hours of benchwork for processing upto 192 samples, optimizing laboratory efficiency.

Internal Control

Built-in internal controls are included to ensure consistent and reliable performance throughout the workflow.

Indexing/Barcoding Capacity

Supports indexing of up to 192 samples, allowing high-throughput sequencing and efficient sample multiplexing.

Analysis & Reporting

Features simplified data analysis with proprietary software, enabling fast, accurate, and user-friendly reporting for streamlined interpretation

Read Length

Generates paired-end sequencing reads of 2×150 bp, delivering high-quality and detailed genetic information.

High-Risk HPV Genotypes

These genotypes are classified as **high-risk and Probably High Risk** due to their strong association with **cervical cancer and have been detected in 99.7%**.

Low-Risk HPV Genotypes

These types are considered low-risk as they are typically associated with benign conditions such as **genital warts and not carcinogenic**.



Note: For Research Use Only (RUO)

STIs Covered by HPV-STI Genomap Kit

Bacterial STIs	Viral STIs
Chlamydia trachomatis (CT)	*Herpes simplex virus type 1 (HSV1)*
Neisseria gonorrhoeae (NG)	*Herpes simplex virus type 2 (HSV2)*
Mycoplasma genitalium (MG)	*Varicella zoster virus (VZV)*
Trichomonas vaginalis (TV)	
Treponema pallidum (TP)	
Haemophilus ducreyi (HD)	
Ureaplasma urealyticum (UU)	
Ureaplasma parvum (UP)	
Mycoplasma hominis (MH)	
Chlamydia serovars: L1, L2, B, D, E, F & G	



UNCODED HPV-STI Kit Genomap Configurations

Kit Name	Catalog No.	Reaction	Storage
HPV-STI Genomap	10215	96	-20

Indexing options for processing over 192 samples are available upon request.



Why Choose HPV-STI Genomap by UNCODED?

Designed for NGS-enabled labs to streamline detection, analysis, and reporting—delivering actionable insights with exceptional efficiency.

All-in-One Profiling: Detect HPV and multiple STIs in a single assay.

Empower surveillance and population-scale research with targeted, reliable data for impactful public health decisions.

Drive clinical and translational breakthroughs through advanced genotype mapping, epidemiology, and precision research capabilities.

DECODEING MULTI-OMICS WITH UNCODED BY PREMAS LIFE SCIENCES

Uncoded is an in-house brand by Premas Life Sciences, created to make high-quality multi-omics solutions accessible—Made in India, for the world. With over 18 years of legacy and 900+ years of combined team expertise, Premas has enabled breakthroughs across genomics, proteomics, biopharma, and healthcare in India.

Uncoded is more than products—it's a movement to advance life sciences with reliable, cost-effective, and globally aligned NGS tools and multi-omics platforms made by scientists, for scientists.

WHAT WE STAND FOR



uncoded
DNA & BEYOND

R&D & MANUFACTURING FACILITY

E-48/3, First Floor Okhla Phase II,
New Delhi – 110020, India

uncoded@premaslifesciences.com

premas
life sciences